Main menu
Edison Group
  • Home
  • Equities

    Equities

    View All Equities

    Equities by Sector

    Vection Technologies

    MCap

    AUD28m

    Last close

    AUD0.02

    ▲ −0.01 (−33.33%)

    Biodexa Pharmaceuticals

    MCap

    USD3m

    Last close

    USD5.11

    ▲ 1.61 (46.00%)

    Pharnext

    MCap

    EUR1m

    Last close

    EUR0.10

    ▲ 0.03 (42.86%)

  • Sectors

    Sectors

  • Investment Strategy

    Investment Strategy

    View All

    Latest

  • Thematics

    Thematics

    View All Thematics

    Latest

Biodexa Pharmaceuticals (NASDAQ: BDRX)

Currency in USD

Last close As at 06/12/2023

USD5.11

▲ 1.61 (46.00%)

Market capitalisation

USD3m

Biodexa Pharmaceuticals (formerly Midatech) is a clinical-stage biopharmaceutical company focused on oncology and rare and orphan indications. Lead candidate MTX110 is in Phase I clinical studies in aggressive rare/orphan brain cancer indications. The preclinical pipeline includes MTD217, targeting leptomeningeal disease.

The brain cancer space comes with a high risk-reward trade off, although successful therapeutics stand to benefit materially given the unmet need. The glioblastoma therapeutics market is a $3–5bn opportunity with only a handful of drugs approved, highlighting the potential for novel therapeutics.

Latest Insights

View More

Healthcare | Flash note

Biodexa Pharmaceuticals — Tolimidone licensing expands clinical pipeline

Healthcare | Flash note

Biodexa Pharmaceuticals — Acquisition of Varian Bio to bolster pipeline

Healthcare | Update

Biodexa Pharmaceuticals — Pivoting out of a challenging FY22

Healthcare | Flash note

Midatech Pharma — Development pipeline expands with MTD217
Midatech Pharma_resized
Visit Website

Sector

Healthcare

Equity Analyst

Soo Romanoff

Soo Romanoff

Managing Director - Head of Content, Healthcare

Nidhi Singh

Nidhi Singh

Analyst

Arron Aatkar

Associate analyst

Key Management

  • Dr Stephen Parker

    Chairman

  • Stephen Stamp

    CEO and CFO

Balance Sheet

Forecast net debt (£m)

N/A

Forecast gearing ratio (%)

N/A

Share Price Performance

Price Performance
% 1M 3M 12M
Actual 33.4 1.8 (99)
Relative 20.7 (1.4) (99.1)
52 week high/low US$16.2/US$0.1

Financials

Following a strategic pivot in early 2023, Biodexa is now positioned as a therapeutics company with a focus on oncology and rare/orphan indications. The current pipeline focus is on the legacy Phase I asset, MTX110, currently undergoing clinical studies in aggressive brain cancers such as glioblastoma (Phase Ib trial ongoing) and diffuse intrinsic pontine glioma, a very rare pediatric cancer. Biodexa has added a new preclinical programme, MTD217, targeting leptomeningeal disease, a secondary CNS cancer with poor prognosis. It recently announced completion of a Phase I study of MTX110 in the treatment of children with newly diagnosed diffuse midline gliomas; full results are expected in Q124. To bolster its pipeline further, Biodexa announced the proposed acquisition of Varian Biopharmaceuticals in May 2023. H123 ended with a £5.23m cash balance, supported by a $6m private placement and $3.3m direct offering, providing a cash runway to Q124.

Y/E Dec Revenue (£m) EBITDA (£m) PBT (£m) EPS (p) P/E (x) P/CF (x)
2021A 0.6 (6.6) (6.1) (6.78) N/A N/A
2022A 0.7 (8.6) (8.5) (1.55) N/A N/A
2023E N/A N/A N/A N/A N/A N/A
2024E N/A N/A N/A N/A N/A N/A

Research

Flash note

Healthcare

Biodexa Pharmaceuticals — Acquisition of Varian Bio to bolster pipeline
Midatech Pharma_resized

Update

Healthcare

Biodexa Pharmaceuticals — Pivoting out of a challenging FY22
Midatech Pharma_resized

Healthcare

Flash note

Biodexa Pharmaceuticals — Tolimidone licensing expands clinical pipeline

Midatech Pharma_resized
View All

Thematics

thematic

Healthcare

Deutsches Eigenkapitalforum (EKF) 2023 healthcare
volition01

thematic

Healthcare

VolitionRx – Decoding the DNA of cancer 

thematic

Healthcare

ASCO 2023 key takeaways

thematic

Healthcare

Machine learning in drug development
View All

Subscribe to Edison

Get access to the very latest content matched to your personal investment style.

Sign up for free